As a new-type foreign trade service provider driven by both technology commercialization and cross-border trading, HiSiaddi has built a "1+2+3+4=1" service system and can supply raw materials of Sodium Hyaluronate from multiple well-known original manufacturers.
As a research-driven foreign trade service provider, HiSiaddi is not limited to promoting only one brand’s technology like single-factory suppliers. We objectively analyze multiple top domestic and international brands with large market shares and share their major technological process advancements and breakthroughs, enabling buyers to access authentic, effective and up-to-date market intelligence.
Contact HiSiaddi customer service for more comprehensive and valuable market information on Sodium Hyaluronate.
1. Bloomage Biotech: Gene-edited streptococcus strains raise fermentation acid yield to 16g/L (industry benchmark: 6–8g/L) and compress fermentation cycles to under 30 hours. A one-time fermentation full molecular weight graded extraction process has been implemented, enabling simultaneous production of pharmaceutical, cosmetic and food-grade raw materials from one batch of fermentation broth and eliminating separate multi-batch fermentation workflows. Nanofiltration purification recovery rate rises from industry average 80% to 95%, unit raw material energy consumption drops by 40%, and production costs for oligosodium hyaluronate fall to 1/20 of traditional enzymatic hydrolysis methods.
2. Focus Freda: Optimized plant-derived peptone nitrogen source replaces chemical nitrogen sources, stabilizing fermentation yield at 14g/L. A lysine hyaluronate biosynthesis process was launched in 2026 and obtained domestic new cosmetic raw material filing, avoiding impurity risks from traditional chemical modification.
1. Single batches can be custom blended with multi-spec molecular weight raw materials, simplifying purchased product categories by 30% and cutting lead times for small-batch multi-spec orders from 7–15 days to 3–5 days.
2. Overall raw material purchase prices drop by 25%–40%; pharmaceutical-grade sodium hyaluronate prices fall from thousands to hundreds of RMB per kilogram, directly reducing raw material costs for downstream medical aesthetics and pharmaceutical manufacturers.
3. Plant nitrogen-source process products meet EU ECOCERT natural cosmetic raw material access standards and can be directly used for EU organic skincare product applications post-procurement.
1. Meiye Biology (Dr. Ling Brand): Authoritative technical certification completed in May 2026, breaking barriers to continuous full molecular weight regulation and enabling stable mass production of sodium hyaluronate covering 500 Da–4000 kDa, resolving the industry-wide limitation of only producing narrow molecular weight fragments. Self-developed directional biological enzymatic cleavage controls molecular weight error within ±5% (industry average ±15%), boosting transdermal absorption rate of small-molecule oligosaccharides (<1 kDa) by 300%.
2. Shanghai Haisco Pharmaceutical Group: Improved directional enzymatic cleavage for pharmaceutical-grade materials; endotoxin levels of ultra-low molecular weight sodium hyaluronate (<3 kDa) drop below 0.01 EU/mg, exceeding the EU/US Pharmacopoeia access limit of 0.03 EU/mg.
3. Focus Freda: Industrialization of ultra-low molecular weight hyaluronic acid via enzymatic cleavage with US invention patent authorization. Acetylated sodium hyaluronate modification process eliminates organic solvents, limiting modified product impurities below 10 ppm.
1. Cosmetic manufacturers can source full-chain raw materials in one stop: high-molecular-weight for water locking, medium-molecular-weight for stratum corneum repair and oligo-molecular for dermal penetration, eliminating multi-supplier sourcing across multiple countries.
2. Raw materials for medical fillers and ophthalmic viscoelastic agents meet mandatory FDA and CEP registration impurity standards for Europe and America, saving buyers third-party impurity re-inspection costs and shortening overseas preparation registration cycles.
1. Focus Freda obtained EU CEP API certificate and South Korean pharmaceutical factory registration for injectable-grade sodium hyaluronate in May 2026; full production lines passed EU GMP on-site audits. Closed sterile crystallization technology delivers finished product microbial limits ≤1 CFU/g.
2. Jingjia Medical: Improved residue-free crosslinking process for medical cross-linked sodium hyaluronate with precisely controllable crosslinking degree ranging from 1%–15%. Products obtained EU Class IV medical aesthetic raw material CE certification to meet demand for long-acting filler formulas in Europe and America.
1. Overseas pharmaceutical and medical aesthetic manufacturers can directly use domestically sourced raw materials for pharmaceutical filings in EU, South Korea and Southeast Asia, eliminating on-site overseas raw material inspections and shortening preparation launch preparation cycles by 6–12 months.
2. End filler products manufactured with residue-free cross-linked raw materials see a 22% reduction in postoperative redness and swelling adverse reactions, lowering end-product market complaints and boosting buyers’ market competitiveness.
Mass production and filing completed for Focus Freda’s lysine hyaluronate and Bloomage Biotech’s zinc chelated sodium hyaluronate. Both modified HA types deliver dual moisturizing and antibacterial effects, differentiated from single moisturizing functions of conventional sodium hyaluronate. Oral targeted HA by Dr. Ling completed pilot testing, with gastric acid resistance rate rising to 82% for compatibility with functional health food formulas.
1. Skincare brands can develop antibacterial repair masks and infant skincare new products using modified HA, lifting differentiated end-product premium pricing by 15%–30%.
2. Food and pet health supplement buyers gain new raw material options for oral HA, tapping into blue ocean markets of oral beauty and pet joint nutrition in Europe and America.
Optimized OBT Optimal Balanced Crosslinking raw material process completed in February 2026, refining molecular arrangement of cross-linked sodium hyaluronate with natural coordination of soft and hard molecular chains without additional chemical crosslinking auxiliaries. Enzymatic degradation resistance in vivo rises by 40%, extending in-vivo retention from 6 months to 9–12 months; products obtained Japan PMDA raw material certification.
Buyers manufacturing long-acting medical aesthetic fillers using this raw material enjoy higher end-user repurchase rates; end-product selling prices can be raised by 20% for equivalent specifications. Simplified formula compatibility reduces auxiliary material addition by 18% and cuts production costs.
Original thermal induction hydrogen bond composite process achieves compounding of high and low molecular weight sodium hyaluronate via intermolecular hydrogen bonds without chemical crosslinkers such as glutaraldehyde. Composite HA solid content reaches 32 mg/ml (conventional products: 20 mg/ml), hyaluronidase degradation resistance rises by 55%, and injection irritation is drastically reduced. Large-scale raw material mass production completed in 2025.
Orthopedic and medical aesthetic buyers eliminate self-blending of high/low molecular weight raw materials; single raw material adapts to joint injection and deep dermal filler formulas, cutting formula R&D cycles by 50%. End injectable products show reduced bruising and swelling incidence, improving clinical recognition of finished products.
Iterated chromatographic purification process reduces foreign protein content of medical ophthalmic-grade sodium hyaluronate to <5 μg/g, far exceeding the USP Pharmacopoeia standard of 20 μg/g. Improved high-temperature stability limits molecular degradation rate to <2% after 121℃ sterilization (industry average: 5%–8%), compatible with disposable pre-filled ophthalmic viscoelastic agent production lines.
Overseas ophthalmic device manufacturers enjoy higher FDA Class III device registration approval rates post-procurement, reducing adverse feedback on end ophthalmic surgical consumables.
1. LG Chem: Commercialized nanoliposomal encapsulation process for sodium hyaluronate with encapsulation rate ≥92%, extending sustained skin release duration of active ingredients from 4 hours to 12 hours.
2. Merz: Microsphere encapsulation of small-molecule HA prevents rapid deactivation upon water contact, extending ambient shelf life from 12 months to 24 months.
Skincare brands can simplify preservative systems post-procurement; naturalized formulas pass EU cosmetic safety audits more easily, cutting end-product shelf loss by 15%.
1. Pharmaceutical End Products: Upgraded purity and stability of ophthalmic viscoelastic agents, joint injection fluids and medical aesthetic filler raw materials reduce end selling prices of surgical consumables and medical aesthetic syringes by 12%–35%, lowering consumer costs for medical treatment and aesthetic procedures.
2. Cosmetic End Products: Diversified formula options of high/low molecular weight and modified HA enable affordable efficacy skincare to incorporate high-activity HA, while high-end anti-aging products deliver enhanced effects, optimizing cost-performance of end consumer goods.
3. Food & Pet End Products: Commercialized oral targeted HA adds functional raw material options for European and American dietary supplements and pet food, improving utilization efficiency of active ingredients in joint care end health supplements and significantly optimizing product efficacy.
Contact HiSiaddi customer service for more comprehensive and valuable market information on Sodium Hyaluronate.
+86-13120989737 
info@hisiaddi.com 
English
